Girdhar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-12-2024
- Company Age 17 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.00 Cr
as on 16-12-2024
- Revenue -56.26%
(FY 2020)
- Profit -96.93%
(FY 2020)
- Ebitda -96.07%
(FY 2020)
- Net Worth 0.02%
(FY 2020)
- Total Assets 1.03%
(FY 2020)
About Girdhar Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹20.00 Cr.
Mukesh Agarwal and Suman Agarwal serve as directors at the Company.
- CIN/LLPIN
U24233DL2007PTC170324
- Company No.
170324
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Girdhar Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Agarwal  | Director | 19-Jan-2013 | Current |
| Suman Agarwal | Director | 01-Feb-2018 | Current |
Financial Performance and Corporate Structure Insights of Girdhar Pharmaceuticals.
Girdhar Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 56.26% decrease. The company also saw a substantial fall in profitability, with a 96.93% decrease in profit. The company's net worth moved up by a moderate rise of 0.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Girdhar Pharmaceuticals?
In 2018, Girdhar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Coral Brio Inframanagement Private LimitedActive 12 years 10 monthsMukesh Agarwal is a mutual person
Chandra Laxmi Hospital Private LimitedActive 21 years 6 monthsMukesh Agarwal and Suman Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 20 Jan 2024 | ₹20.00 Cr | Open |
How Many Employees Work at Girdhar Pharmaceuticals?
Unlock and access historical data on people associated with Girdhar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Girdhar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Girdhar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
